Fase 2
Quiénes somos
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Estudio de fase 2 de CA102N combinado con TAS-102 comparado con bevacizumab combinado con TAS-102 en sujetos con cáncer colorrectal metastásico recidivante y/o refractario.
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Estudio de CNA3103 (células CAR-T autólogas dirigidas a LGR5) administrado a sujetos con cáncer colorrectal metastásico.
RC48-ADC combinado con bevacizumab en cáncer colorrectal avanzado HER2-positivo
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Immunotherapy for Third Line Metastatic Colorectal Cancer
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
